9 March 2020 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice on four new medicines. 

All of the medicines were considered through the SMC’s Patient and Clinician Engagement (PACE) process, which is used for medicines to treat end of life and very rare conditions.

Lorlatinib (Lorviqua) was accepted for interim use subject to ongoing evaluation and future reassessment by SMC.

Read SMC press release